Single-payer pharmacare is a cure worse than what ails the system
A federal intrusion that disrupts coverage for three-quarters of the population, requires tax hikes and spending cuts, and leads to less drug access hardly seems like a political winner. But neither is silence on the other side of the debate.
As we approach the 2019 federal election campaign, we seem to be moving towards to a major policy conflict between political parties on pharmacare and the federal role.
The debate will hinge on whether we should pursue targeted or sweeping reforms, whether we prioritize clinician and patient choice...
SPONSORED CONTENT
Get Weekend Point of View Newsletter
A round up of the past week’s opinion writers and columnists on Saturdays and Sundays.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
